In type 2 diabetes patients, dulaglutide improved blood sugar control through hormonal changes in leptin and obestatin rather than through weight or fat loss alone.
Leptin decrease + obestatin increase = glycemic improvementChanges in these two hormones independently predicted HbA1c reduction, while changes in BMI or abdominal fat did not
What the researchers found
Decreases in leptin and increases in obestatin independently predicted HbA1c reduction with dulaglutide, while changes in BMI or abdominal fat were not associated with glycemic improvement. Responders showed greater beta-cell function improvement and more pronounced food craving reductions.
Why it matters
Demonstrates that GLP-1 drug benefits extend beyond weight loss through hormonal modulation of leptin and obestatin, potentially enabling biomarker-based prediction of treatment response.
The numbers in context
n=82 enrolled, 67 completed; dulaglutide 0.75 mg weekly; 24 weeks; leptin decrease and obestatin increase independently associated with HbA1c reduction
How the study worked
24-week prospective observational study. 82 T2DM patients with HbA1c ≥7.0% received dulaglutide 0.75 mg weekly. Abdominal CT, food craving questionnaires, and fasting levels of leptin, adiponectin, obestatin, ghrelin, and resistin assessed at baseline and week 24. Responders defined as HbA1c reduction ≥0.5% and/or HbA1c <7.0%. Multivariable regression identified predictors of glycemic improvement.
Who was studied
82 adults with type 2 diabetes and HbA1c ≥7.0% despite standard therapy, treated with dulaglutide 0.75 mg weekly for 24 weeks
What this study cannot tell us
Single-arm, no control group; n=67 completers; low-dose only (0.75 mg); 24-week duration; observational (association not causation); 18% dropout.
How to read the evidence
This is a prospective observational study with 67 completers, published in a diabetes journal. While well-designed with CT imaging and comprehensive hormone panels, the lack of a control group and modest sample size place it at moderate evidence strength.
When this study was published
Published in 2025, this is very recent research that provides new mechanistic insights into how GLP-1 drugs work beyond weight loss — a timely question as these drugs see explosive growth in clinical use.
The bigger picture
As GLP-1 drugs become first-line treatments for diabetes and obesity, understanding their mechanisms beyond weight loss is increasingly important. This study adds evidence that GLP-1 receptor agonists modulate a network of appetite-related hormones and adipokines. The identification of leptin and obestatin as independent predictors of response could contribute to personalized medicine approaches — testing hormone levels to guide GLP-1 therapy decisions.
Questions still open
- Do leptin and obestatin changes also predict response to other GLP-1 drugs like semaglutide or tirzepatide?
- Would higher-dose dulaglutide (1.5 mg) produce even greater hormonal shifts and better glycemic outcomes?
- Could baseline leptin or obestatin levels be used prospectively to predict who will respond to GLP-1 therapy?
Common questions
What is obestatin and why does it matter here?
Does this mean you can benefit from dulaglutide even without losing weight?
Read the original research
Glycemic Improvement with Low-Dose Dulaglutide Is Associated with Leptin and Obestatin Modulation in Type 2 Diabetes Mellitus.
Diabetes & metabolism journal
Citation
Jung, Inha; Choi, Hangseok; Choi, In Young; Cho, Hyun Joo; Park, So Young; Lee, Da Young; Seo, Ji A; Kim, Nan Hee; Yu, Ji Hee. (2025). Glycemic Improvement with Low-Dose Dulaglutide Is Associated with Leptin and Obestatin Modulation in Type 2 Diabetes Mellitus.. Diabetes & metabolism journal. https://doi.org/10.4093/dmj.2025.0681